Given the loss of apoptotic response to DNA damage, CLL with TP53 or ATM deletions or mutations predictably confers inferior survival outcomes with conventional chemotherapy [16,18,19,27]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.